In another prospective study of patients with active Crohn’s disease, major depressive disorder at baseline was an independent risk factor for failure to achieve quiescence of the disease after treatment with the anti-TNF agent infliximab, as well as for retreatment compared to patients without major depressive disorder [131]. The gene discussed is TNF; the disease is major depressive disorder.